



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 31/4985, A61P 9/08, 15/10</p>	A1	<p>(11) International Publication Number: WO 00/15228</p> <p>(43) International Publication Date: 23 March 2000 (23.03.00)</p>
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>(21) International Application Number: PCT/US99/19466</p> <p>(22) International Filing Date: 26 August 1999 (26.08.99)</p> <p>(30) Priority Data: 09/154,051 16 September 1998 (16.09.98) US</p> <p>(71) Applicant: ICOS CORPORATION [US/US]; 22021 20th Avenue S.E., Bothell, WA 98021 (US).</p> <p>(72) Inventors: DAUGAN, Alain, Claude-Marie; 100, route de Versailles, F-78163 Marly Le Roi Cedex (FR). GELLIBERT, Françoise; 100, route de Versailles, F-78163 Marly Le Roi Cedex (FR).</p> <p>(74) Agent: NAPOLI, James, J.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).</p> </div> <div style="width: 48%;"> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> </div> </div>		
<p>(54) Title: COMBINATIONS OF TETRACYCLIC CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS WITH FURTHER THERAPEUTIC AGENTS</p>		
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>(I)</p> </div> <div style="text-align: center;"> <p>(a)</p> </div> </div>		
<p>(57) Abstract</p> <p>A compound of formula (I) and salts and solvates thereof, in which: R⁰ represents hydrogen, halogen, or C₁-alkyl; R¹ represents hydrogen, C₁-6-alkyl, C₂-6-alkenyl, C₂-6-alkynyl, haloC₁-6-alkyl, C₃-acycloalkyl, C₃-acycloalkylC₁-3-alkyl, arylC₁-3-alkyl, or heteroarylC₁-3-alkyl; R² represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and R³ represents hydrogen or C₁-3-alkyl, or R¹ and R³ together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CN	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

**COMBINATIONS OF TETRACYCLIC CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE
INHIBITORS WITH FURTHER THERAPEUTIC AGENTS**

5

FIELD AND BACKGROUND OF THE INVENTION


This invention relates to a series of
tetracyclic derivatives, to processes for their
10 preparation, pharmaceutical compositions containing
them, and to their use as therapeutic agents. In
particular, the invention relates to tetracyclic
derivatives that are potent and selective inhibitors
of cyclic guanosine 3',5'-monophosphate specific
15 phosphodiesterase (cGMP-specific PDE) having utility
in a variety of therapeutic areas where such inhibi-
tion is thought to be beneficial, including the
treatment of cardiovascular disorders and erectile
dysfunction.

20

SUMMARY OF THE INVENTION

Thus, according to a first aspect, the
present invention provides compounds of formula (I)

25



30

(I)

- 2 -

and salts and solvates (e.g., hydrates) thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6} alkyl;

5 R^1 represents hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl C_{1-3} alkyl, aryl C_{1-3} alkyl, or hetero-aryl C_{1-3} alkyl;

10 R^2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring

15




20 attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and

25 R^3 represents hydrogen of C_{1-3} alkyl, or R^1 and R^3 together represent a 3- or 4-membered alkyl or alkenyl chain.

There is further provided by the present invention a subgroup of compounds for formula (I), the subgroup comprising compounds of formula (Ia)

- 3 -



(Ia)

and salts and solvates (e.g., hydrates) thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6} alkyl;

R^1 represents hydrogen, C_{1-6} alkyl, halo C_{1-6} -alkyl, C_{3-8} cycloalkyl C_{1-3} alkyl, aryl C_{1-3} alkyl, or heteroaryl C_{1-3} alkyl; and

R^2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring




attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring A is a 5- or 6-membered ring which can be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen.

There is yet further provided by the present invention a further subgroup of compounds of

- 4 -

formula (I), the compounds comprising compounds of formula (Ib)



(Ib)

and solvates (e.g., hydrates) thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6} -alkyl;

R^1 represents hydrogen or C_{1-6} alkyl;

R^2 represents the bicyclic ring



or



which can be optionally substituted by one or more groups selected from halogen and C_{1-3} alkyl; and

R^3 represents hydrogen or C_{1-3} alkyl.

Within R^1 above, the term "aryl" as part of an aryl C_{1-3} alkyl group means phenyl or phenyl substituted by one or more (e.g., 1, 2, or 3) substituents selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy, and methylenedioxy. The term "heteroaryl" as part of a heteroaryl C_{1-3} alkyl group means thienyl, furyl, or pyridyl, each optionally substituted by one or more (e.g., 1, 2, or 3) substituents selected from halo-


- 5 -

gen, C₁₋₆alkyl, and C₁₋₆alkoxy. The term "C₃₋₈cycloalkyl" as a group or part of a C₃₋₈cycloalkylC₁₋₃alkyl group means a monocyclic ring comprising three to eight carbon atoms. Examples of suitable cycloalkyl rings include the C₃₋₆cycloalkyl rings cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Within R² above, optional benzene ring substituents are selected from one or more (e.g., 1, 2, or 3) atoms or groups comprising halogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, CO₂R^b, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, cyano, nitro, and NR^aR^b, where R^a and R^b are each hydrogen or C₁₋₆alkyl, or R^a also can represent C₂₋₇alkanoyl or C₁₋₆alkylsulphonyl. Optional substituents for the remaining ring systems are selected from one or more (e.g., 1, 2, or 3) atoms or groups comprising halogen, C₁₋₆alkyl, C₁₋₆alkoxy, and arylC₁₋₃alkyl as defined above. The bicyclic ring



can, for example, represent naphthalene, a heterocycle such as benzoxazole, benzothiazole, benzisoxazole, benzimidazole, quinoline, indole, benzothio-
phenene, benzofuran, or



- 6 -

wherein n is an integer 1 or 2 and X and Y each can represent CH₂, O, S, or NH.

In the above definitions, the term "alkyl," as a group or part of a group, means a
5 straight chain or, where available, a branched chain moiety containing the indicated number of carbon atoms. For example, it can represent a C₁₋₄alkyl function as represented by methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, and t-butyl. The term
10 "alkenyl" as used herein includes straight chained and branched alkenyl groups containing the indicated number of carbon atoms, such as vinyl and allyl groups. The term "alkynyl" as used herein includes straight chained and branched alkynyl groups con-
15 taining the indicated number of carbon atoms, suitably acetylene.

The term "halogen" herein means a fluorine, chlorine, bromine, or iodine atom.

The term "haloC₁₋₆alkyl" means an alkyl
20 group as defined above comprising one to six carbon atoms substituted at one or more carbon atoms by one or more (e.g., 1, 2, or 3) halogen atoms. Similarly, a haloC₁₋₆alkoxy group is a haloC₁₋₆alkyl group as defined above linked to the R² benzene ring via an
25 oxygen atom. Examples of haloC₁₋₆alkyl groups include trifluoromethyl and 2,2,2-trifluoroethyl. An example of a haloC₁₋₆alkoxy group is trifluoromethoxy. The term "C₂₋₇alkanoyl" means a C₁₋₆alkanoyl group where the C₁₋₆alkyl portion is as defined
30 above. An example of a suitable C₂₋₇alkanoyl group is the C₂alkanoyl group acetyl.

When R⁰ is a halogen atom or a C₁₋₆alkyl group, this substituent can be sited at any avail-

- 7 -

able position on the phenyl portion of the tetra-cyclic ring. However, a particular site of attachment is the ring 10-position.

5 The compounds of formula (I) can contain two or more asymmetric centers, and, thus, can exist - as enantiomers or diastereoisomers. In particular, in formula (I) above, two ring chiral centers are denoted with asterisks. It is to be understood that the invention includes both mixture and separate
10 individual isomers of the compounds of formula (I).

 The compounds of formula (I) also can exist in tautomeric forms, and the invention includes both mixtures and separate individual tautomers thereof.

15 The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic center are acid addition salts formed with pharmaceutically acceptable acids. Examples include the hydrochloride, hydrobromide, sulfate or bisulfate,
20 phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulphonate, and p-toluenesulphonate salts. Compounds of formula (I) also can provide pharmaceutically acceptable metal
25 salts, in particular alkali metal salts, with bases. Examples include the sodium and potassium salts.

 A particular group of compounds of the invention are those compounds of formula (I) in which R^0 is hydrogen or halogen (e.g., fluorine),
30 especially hydrogen.


 Another particular group of compounds of the invention are those compounds of formula (I) in which R^1 represents hydrogen, C_{1-4} alkyl, halo C_{1-4} alkyl,

- 8 -

C₃₋₆cycloalkyl, C₃₋₆cycloalkylmethyl, pyridylC₁₋₃alkyl, furylC₁₋₃alkyl, or optionally substituted benzyl.

Within this particular group of compounds, examples of C₁₋₄alkyl groups are methyl, ethyl, n-propyl, i-propyl, and n-butyl. Examples of C₃₋₆cycloalkylmethyl groups are cyclopropylmethyl and cyclohexylmethyl. Examples of optionally substituted, benzyl groups include benzyl and halobenzyl (e.g., fluoro-benzyl).

A further group of compounds of the invention are those compounds of formula (I) in which R² represents an optionally substituted benzene, thiophene, furan, pyridine, or naphthalene ring, or an optionally substituted bicyclic ring




wherein n is 1 or 2, and X and Y are each CH₂ or O. Within this particular group of compounds, examples of substituted benzene groups are benzene substituted by one of halogen (e.g., chlorine), hydroxy, C₁₋₃alkyl (e.g., methyl, ethyl, or i-propyl), C₁₋₃alkoxy (e.g., methoxy or ethoxy), CO₂R^b, halomethyl (e.g., trifluoromethyl), halomethoxy (e.g., trifluoromethoxy), cyano, nitro, or NR^aR^b wherein R^a and R^b are each hydrogen or methyl, or R^a is acetyl, or benzene substituted by dihalo (e.g., dichloro) or by C₁₋₃alkoxy (e.g., methoxy) and one of halogen (e.g., chlorine) and hydroxy. An example of a substituted

- 9 -

thiophene ring is a halo (e.g., bromo) substituted thiophene ring.

A still further particular group of compounds of formula (I) are those where R^3 represents hydrogen or R^1 and R^3 together represent a 3-membered alkyl chain.

A preferred group of compounds of the invention are the cis isomers of formula (I) represented by formula (Ic)



(Ic)

and mixtures thereof with their cis optical enantiomers, including racemic mixtures, and salts and solvates (e.g., hydrates) of these compounds in which R^0 is hydrogen or halogen (e.g., fluorine), especially hydrogen, and R^1 , R^2 , and R^3 are as defined previously.

The single isomers represented by formula (Ic), i.e., the 6R, 12aR isomers, are particularly preferred.

Within the above definitions, R^1 preferably can represent C_{1-4} alkyl (e.g., methyl, ethyl, isopropyl, and n-butyl), C_{3-6} cycloalkyl (e.g., cyclopentyl) or C_{3-6} cycloalkylmethyl (e.g., cyclopropylmethyl).

R^2 preferably can represent a substituted benzene ring such as benzene substituted by C_{1-3} -

- 10 -

alkoxy (e.g., methoxy) or by C₁₋₃alkoxy (e.g., methoxy) and halogen (e.g., chlorine), particularly 4-methoxyphenyl or 3-chloro-4-methoxyphenyl, or R² preferably can represent 3,4-methylenedioxyphenyl.

5 A particularly preferred subgroup of compounds according to the present invention are compounds wherein R⁰ represents hydrogen.

A further preferred subgroup includes compounds wherein R¹ is selected from hydrogen, methyl, and isopropyl.

10 Preferably, R² represents the unsubstituted bicyclic ring



15
20 A still further subgroup of compounds of formula (I), are compounds wherein R³ represents hydrogen or methyl.

It is to be understood that the present invention covers all appropriate combinations of particular and preferred groupings hereinabove.

Particular individual compounds of the invention include:

30 *cis*-2,3,6,7,12,12a-hexahydro-2-(4-pyridyl-methyl)-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

- 11 -

- cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]furan-5-yl)-2-methyl-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methylpyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione;
- cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione;
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopropylmethyl-6-(4-methoxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- (6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- (5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo-[1",2":4'5']pyrazino[2',1':6,1]pyrido[3,4-b]indole-5-1,4-dione;

- 12 -

(6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2', 1':6, 1]pyrido[3, 4-b]indole-1, 4-dione;

5 (6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-6-(5-benzofuranyl)-pyrazino[2', 1':6, 1]pyrido[3, 4-b]-indole-1, 4-dione; -

(3S, 6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2', 1':6, 1]pyrido[3, 4-b]indole-1, 4-dione;

10 (3S, 6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-6-(5-benzofuranyl)-2, 3-dimethyl-pyrazino[2', 1':6, 1]pyrido[3, 4-b]indole-1, 4-dione;

(6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2', 1':6, 1]pyrido[3, 4-b]indole-1, 4-dione; and physiologically acceptable solvates (e.g., hydrates) thereof.

Specific compounds of the invention are:

20 (6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-2-methyl-6-(3, 4-methylenedioxyphenyl)-pyrazino[2', 1':6, 1]pyrido[3, 4-b]indole-1, 4-dione; and

(6R, 12aR)-2, 3, 6, 7, 12, 12a-hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2', 1':6, 1]pyrido[3, 4-b]indole-1, 4-dione; and physiologically acceptable solvates (e.g., hydrates) thereof.

25

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

30 It has been shown that compounds of the present invention are potent and selective inhibitors of cGMP-specific PDEs 1, 5, and 6, and particularly PDE5. Thus, compounds of formula (I) are of interest for use in therapy, specifically for the

- 13 -

treatment of a variety of conditions where selective inhibition of PDE5 is considered to be beneficial.

In summary, the biochemical, physiological, and clinical effects of PDE5 inhibitors suggest their utility in a variety of disease states in which modulation of smooth muscle, renal, hemostatic, inflammatory, and/or endocrine function is desirable. The compounds of formula (I), therefore, have utility in the treatment of a number of disorders, including stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, acute respiratory distress syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., postpercutaneous transluminal coronary or carotid angioplasty, or post-bypass surgery graft stenosis), peripheral vascular disease, vascular disorders, such as Raynaud's disease, thrombocytopenia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).

An especially important use is the treatment of male erectile dysfunction, which is one form of impotence and is a common medical problem. Impotence can be defined as a lack of power, in the male, to copulate and can involve an inability to achieve penile erection or ejaculation, or both. The incidence of erectile dysfunction increases with age, with about 50% of men over the age of 40 suffering from some degree of erectile dysfunction.

- 14 -

Many compounds have been investigated for their therapeutic potential in the treatment of MED, including phenoxybenzamine, papaverine, prostaglandin E1 (PGE1), and phentolamine. These compounds, either alone or in combination, are typically self-administered by intracavernosal (i.c.) injection. While such treatments are effective, a treatment that is less invasive than injection therapy is preferred because pain, priapism, and fibrosis of the penis are associated with the i.c. administration of these agents.

For example, alprostadil (i.e., prostaglandin E1) delivered by intraurethral deposition has been approved for the treatment of MED. However, clinical studies showed that this route of administration is not effective in all patients. In addition, phentolamine and apomorphine are being evaluated as oral and sublingual therapies for MED, but neither compound has demonstrated efficacy across a broad range of subjects. Potassium channel openers (KCO) and vasoactive intestinal polypeptide (VIP) also have been shown to be active i.c., but cost and stability issues could limit development of the latter. An alternative to the i.c. route is the use of glyceryl trinitrate (GTN) patches applied to the penis, which has been shown to be effective but produces side effects in both patient and partner.

As an alternative to pharmacological treatment, a variety of penile prostheses have been used to assist achievement of an erection. The short-term success rate is good, but problems with infection and ischemia, especially in diabetic men,

- 15 -

make this type of treatment a final option rather than a first-line therapy.


Because of the disadvantages of prior treatments for MED, new strategies to improve
5 erectile response that exploit different physiological mechanisms are being investigated. One area of investigation is increasing the intracellular concentration of cGMP by providing a new type of oral therapy for the treatment of MED.

10 Increasing cGMP concentration is an important step in the physiology of penile erections. A penile erection is caused by neural stimuli that ultimately cause vasodilation of the arteries and sinusoidal spaces of the corpus
15 cavernosum. Research indicates that nitric oxide plays a central role in this vasodilation.

In particular, atrial natriuretic peptides (ANP) and nitric oxide (NO, sometimes referred to as endothelium-derived relaxing factor or EDRF) relax
20 smooth muscle by increasing guanylyl cyclase activity, which raises intracellular cGMP concentration. Intracellular cGMP is hydrolyzed by phosphodiesterases (PDEs), thereby terminating the action of the cyclic nucleotide. PDE5 is the major
25 cGMP hydrolyzing enzyme in vascular smooth muscle. Accordingly, PDE5 inhibition potentiates the relaxant effects of ANP and nitric oxide by increasing the cGMP levels. Therefore, a compound that
30 inhibits the PDE5 enzyme (and thereby indirectly inhibits the hydrolysis of cGMP) should potentiate the vascular response to nitric oxide, thereby facilitating the achievement and maintenance of erection.

- 16 -

PDE5 inhibitors have potential for use in treating male erectile dysfunction (MED), hypertension, heart failure, and other disease states because of their ability to facilitate the action of ANP and NO. For example, sildenafil, a PDE inhibitor showing little selectivity with respect to PDE6, has the structure:



and has shown efficacy in oral administration clinical trials for MED, which supports the hypothesis that augmenting normal or subnormal guanylyl cyclase stimuli has therapeutic benefits.

It is envisioned, therefore, that compounds of formula (I) are useful in the treatment of erectile dysfunction. Furthermore, the compounds can be administered orally, thereby obviating the disadvantages associated with intracavernosal administration. Thus, the present invention concerns the use of compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manu-

- 17 -

facture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man.

5 It also has been observed that human corpus cavernosum contains three distinct PDE enzymes (see A. Taher et al., *J. Urol.*, 149, p. 285A (1993)), one of which is the cGMP-specific PDE5. As a consequence of the selective PDE5 inhibition exhibited by compounds of the present invention, the
10 the present compounds sustain cGMP levels, which in turn mediate relaxation of the corpus cavernosum tissue and consequent penile erection.

Although the compounds of the invention are envisioned primarily for the treatment of
15 erectile dysfunction in humans, such as male erectile dysfunction and female sexual dysfunction, including orgasmic dysfunction related to clitoral disturbances, they also can be used for the treatment of premature labor and dysmenorrhea.

20 It is understood that references herein to treatment extend to prophylaxis, as well as treatment of established conditions.

It also is understood that "a compound of formula (I)," or a physiologically acceptable salt
25 or solvate thereof, can be administered as the neat compound, or as a pharmaceutical composition containing either entity.

A further aspect of the present invention is providing a compound of formula (I) for use in
30 the treatment of stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, acute respiratory distress

- 18 -

syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., post-PTCA or post-bypass graft stenosis), peripheral vascular disease, vascular disorders such as Raynaud's disease, thrombo-
5 cythemia, inflammatory diseases, prophylaxis of myocardial infarction, prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm
10 labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

According to another aspect of the present invention, there is provided the use of a compound
15 of formula (I) for the manufacture of a medicament for the treatment of the above-noted conditions and disorders.

In a further aspect, the present invention provides a method of treating the above-noted conditions and disorders in a human or nonhuman animal
20 body which comprises administering to said body a therapeutically effective amount of a compound of formula (I).

Compounds of the invention can be administered by any suitable route, for example by oral,
25 buccal, inhalation, sublingual, rectal, vaginal, transurethral, nasal, topical, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary)
30 administration. Parenteral administration can be accomplished using a needle and syringe, or using a high pressure technique, like POWDERJECT™. Oral administration generally is preferred.

- 19 -

With respect to treating sexual dysfunction and particularly erectile dysfunction in humans, oral administration of the compounds of the invention is the preferred route. Oral administration is the most convenient and avoids the disadvantages associated with intracavernosal administration. For patients suffering from a swallowing disorder or from impairment of drug absorption after oral administration, the drug can be administered parenterally, e.g., sublingually or buccally.

For administration to man in the curative or prophylactic treatment of the conditions and disorders identified above, oral dosages of a compound of formula (I) generally are about 0.5 to about 1000 mg daily for an average adult patient (70 kg). Thus, for a typical adult patient, individual tablets or capsules contain 0.2 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal, or sublingual administration typically are 0.1 to 500 mg per single dose as required. In practice, the physician determines the actual dosing regimen which is most suitable for an individual patient, and the dosage varies with the age, weight, and response of the particular patient. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this invention.

For human use, a compound of the formula (I) can be administered alone, but generally is

- 20 -

administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the compound can be administered orally, buccally, or sublingually in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents (e.g., methylcellulose, a semisynthetic glyceride such as witopsol, or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters, or mixtures of PEG-8 and caprylic/capric glycerides). A compound also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.

For veterinary use, a compound of formula (I) or a nontoxic salt thereof, is administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.

Thus, the invention provides in a further aspect a pharmaceutical composition comprising a

- 21 -

compound of the formula (I), together with a pharmaceutically acceptable diluent or carrier therefor.

There is further provided by the present invention a process of preparing a pharmaceutical composition comprising a compound of formula (I), which process comprises mixing a compound of formula (I), together with a pharmaceutically acceptable diluent or carrier therefor.

In a particular embodiment, the invention includes a pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

A compound of formula (I) also can be used in combination with other therapeutic agents which can be useful in the treatment of the above-mentioned and other disease states. The invention thus provides, in another aspect, a combination of a compound of formula (I), together with a second therapeutically active agent.

A compound of formula (I) can be used in the preparation of a medicament for co-administration with the second therapeutically active agent in treatment of conditions where inhibition of a cGMP-specific PDE is beneficial. In addition, a compound of formula (I) can be used in the preparation of a medicament for use as adjunctive therapy with a second therapeutically active compound to treat such conditions. Appropriate doses of known second therapeutic agents for use in combination with a

- 22 -

compound of formula (I) are readily appreciated by those skilled in the art.

In particular, because compounds of the present invention maintain cGMP levels, the compounds of formula (I) can provide beneficial anti-platelet, antineutrophil, antivasospastic, vasodilatory, natriuretic, and diuretic activities, as well as potentiate the effects of endothelium-derived relaxing factor (EDRF), gastric NO administration, nitrovasodilators, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and endothelium-dependent relaxing agents such as bradykinin, acetylcholine, and 5-HT₁.

The present selective PDE5 inhibitors in combination with vasodilators, including nitric oxide and nitric oxide donors and precursors, such as the organic nitrate vasodilators which act by releasing nitric oxide *in vivo*, are especially useful in treatment of angina, congestive heart failure, and malignant hypertension (e.g., pheochromocytoma). Related to the capacity of the present PDE5 inhibitors to potentiate nitric oxide donors and precursors is their ability, in spontaneously hypertensive rats, to reverse the desensitization to these agents that occurs with chronic use.

Examples of vasodilators that can be used in conjunction with the compounds of formula (I) include, but are not limited to, (a) organic nitrates, such as nitroglycerin, isosorbide dinitrate, pentaerythrityl tetranitrate, isosorbide-5-mononitrate, propatyl nitrate, trolnitrate, nicro-andil, mannitol hexanitrate, inositol hexanitrate, N-[3-nitratopivaloyl]-L-cysteine ethyl ester, (b)

- 23 -

organic nitrites, like isoamyl nitrite, (c) thio-nitrites, (d) thionitrates, (e) S-nitrosothiols, like S-nitroso-N-acetyl-D,L-penicillamine, (f) nitrosoproteins, (g) substituted furoxanes, such as
5 1,2,5-oxadiazole-2-oxide and furazan-N-oxide, (h) substituted sydnominines, such as molsidomine and mesocarb, (i) nitrosyl complex compounds, like iron nitrosyl compounds, especially sodium nitroprusside, and (j) nitric oxide (NO) itself.

10 Other classes of therapeutic agents that can be used in conjunction with the compounds of formula (I), in addition to vasodilators, include, but are not limited to, α -adrenergic blockers, mixed α , β -blockers, prostaglandin EI (PGEI) and prosta-
15 cyclin (PGI2), angiotensin converting enzyme inhibitors (ACE inhibitors), neutral endopeptidase (NEP) inhibitors, centrally acting dopaminergic agents (such as apomorphine), vasoactive intestinal peptides (VIP), calcium channel blockers, and compounds
20 like thiazides.

Alpha-adrenergic blockers inhibit vasoconstriction in the corpus cavernosum. Because PDE5 inhibitors enhance vasodilation of the same smooth muscle tissue, a PDE5 inhibitor of formula (I) and
25 an α -adrenergic blocker, like phentolamine or prazosin, or a centrally acting dopaminergic agent, like apomorphine, can be expected to potentiate one another in a treatment for MED or other disorders. Potentiation of mixed α , β -blockers, like carvedilol,
30 which is employed in treatment of hypertension, also is expected. Similarly, α_2 -adrenergic blockers, like yohimbine, can be potentiated.

- 24 -

Prostaglandin E1 enhances relaxation of the corpus cavernosum by increasing the formation of cyclic AMP. Cyclic AMP can be degraded in the corpus cavernosum by PDE3, which is inhibited by cyclic GMP. By maintaining cyclic GMP levels, a PDE5 inhibitor can indirectly inhibit PDE3 activity, and hence block degradation of cyclic AMP. Therefore, a PDE5 inhibitor of formula (I) can be expected to potentiate the activity of PGE1 in the treatment of MED or compounds having similar activities, such as PGI2, in the treatment of pulmonary hypertension, for example.

Angiotensin converting enzyme (ACE) inhibitors block the conversion of angiotensin I into angiotensin II, which causes systemic vasoconstriction and the retention of sodium and water. PDE5 inhibitors cause vasodilation in hypertensive animals, and stimulate the excretion of sodium and water in normotensive animals. Therefore, a PDE5 inhibitor of formula (I) can be combined with an ACE inhibitor to achieve more powerful vasodilatory and natriuretic effects in, for example, treatment of congestive heart failure or hypertensive states.

Neutral endopeptidase (NEP) inhibitors inhibit the degradation of atrial natriuretic peptide (ANP) by NEP. PDE5 inhibitors can be expected to potentiate the action of ANP by inhibiting degradation of its second messenger, cyclic GMP, and, therefore, a compound of formula (I) can potentiate the effects of agents, like NEP inhibitors, that increase blood levels of ANP.

The combination referred to above can be presented for use in the form of a single pharma-

- 25 -

ceutical formulation, and, thus, pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier comprise a further aspect of the invention.

The individual components of such a combination, therefore, can be administered either sequentially or simultaneously from the same or separate pharmaceutical formulations. As is the case for the PDE5 inhibitors of formula (I), a second therapeutic agent can be administered by any suitable route, for example, by oral, buccal, inhalation, sublingual, rectal, vaginal, trans-urethral, nasal, topical, percutaneous (i.e., transdermal), or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration.

In some embodiments, the compound of formula (I) and the second therapeutic agent are administered by the same route, either from the same or from different pharmaceutical compositions. However, in other embodiments, using the same route of administration for the compound of formula (I) and the second therapeutic agent either is impossible or is not preferred. For example, if the second therapeutic agent is nitric oxide, which typically is administered by inhalation, the compound of formula (I) must be administered by a different route. Furthermore, if a compound of formula (I) is used in combination with a nitrate vasodilator, for example, in treatment of an erectile dysfunction, it is preferred that the compound of formula (I) is administered orally and

- 26 -

the vasodilator is administered topically, and preferably in a manner which avoids substantial systemic delivery of the nitrate.

The combination of a compound of formula (I) and a second therapeutic agent is envisioned in the treatment of several disease states. Examples of such treatments are the systemic and topical treatment of male and female sexual dysfunction, wherein a compound of formula (I) is used in combination with phentolamine, prazosin, apomorphine, PDE1, or a vasoactive intestinal peptide. The compound of formula (I) can be administered orally or transurethraly, and the second therapeutic agent can be administered orally, topically, or intracavernosally, for example. Persons skilled in the art are aware of the best modes of administration for each therapeutic agent, either alone or in a combination.

Other disease states that can be treated by a combination of a compound of formula (I) and a second therapeutic agent include, but are not limited to:

- (a) treatment of hypertension using a compound of formula (I) in combination with an α -adrenergic blocker, a mixed α , β -blocker, like carvedilol, a thiazide, sodium nitroprusside, an ACE inhibitor, or a calcium channel blocker;
- (b) treatment of pulmonary hypertension using a compound of formula (I) in combination with inhaled NO or other

- 27 -

inhaled vasodilators, or with PGI2 administered via an IV pump; and

- (c) treatment of chronic obstructive pulmonary disease using a compound of formula (I) in combination with inhaled NO.

Examples of individual compounds of the invention for use in the treatment of erectile dysfunction include:

cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]furan-5-yl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

cis-2,3,6,7,12,12a-hexahydro-2-butyl-(4-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-cyclopropylmethyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

- 28 -

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo-[1",2":4',5']pyrazino[2',1':6,1]pyrido[3,4-b]indole-5-1,4-dione;

cis-2,3,6,7,12,12a-hexahydro-2-cyclopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;

(3S, 6R, 12aR)-2,3,6,7,12,12a-hexahydro-3-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione; and physiologically acceptable salts and solvates (e.g., hydrates) thereof.

Especially useful specific compounds of the invention are:

(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione; and


(3S, 6R, 12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione; and physiologically acceptable salts and solvates (e.g., hydrates) thereof.

Compounds of formula (I) can be prepared by any suitable method known in the art or by the following processes which form part of the present invention. In the methods below, R⁰, R¹, and R² are

- 29 -

as defined in formula (I) above unless otherwise indicated.


Thus, a process (A) for preparing a compound of formula (I) wherein R^3 represents hydrogen
5 comprises treating a compound of formula (II)



(II)

15 in which Alk represents C_{1-6} alkyl, e.g., methyl or ethyl, and Hal is a halogen atom, e.g., chlorine, with a primary amine R^1NH_2 in a suitable solvent, such as an alcohol (e.g., methanol or ethanol) or a
20 mixture of solvents, conveniently at a temperature of from $20^\circ C$ to reflux (e.g., at about $50^\circ C$).

A compound of formula (II) can be conveniently prepared by treating a compound of formula
25 (III)



(III)

- 30 -

with a haloacetyl halide (e.g., chloroacetyl chloride) in a suitable solvent, such as a halo-genated hydrocarbon (e.g., trichloromethane or dichloromethane) or an ether (e.g., tetrahydro-
5 furan), preferably in the presence of a base such as an organic amine (e.g., a trialkylamine such as triethylamine) or an alkali metal carbonate or bi-carbonate (e.g., NaHCO_3). The reaction conveniently can be effected at a temperature of from -20°C to
10 $+20^\circ\text{C}$ (e.g., at about 0°C).


A compound of formula (I) also can be prepared from a compound of formula (III) in a two-step procedure via a compound of formula (II) isolated without purification.

15 Compounds of formula (I) can be prepared as individual enantiomers in two steps from the appropriate enantiomer of formula (III) or as mixtures (e.g., racemates) of either pairs of cis or trans isomers from the corresponding mixtures of
20 either pairs of cis or trans isomers of formula (III).

Individual enantiomers of the compounds of the invention can be prepared from racemates by resolution using methods known in the art for the
25 separation of racemic mixtures into their constituent enantiomers, for examples, using HPLC (high performance liquid chromatography) on a chiral column such as Hypersil naphthylurea.

A compound of formula (III) conveniently
30 can be prepared from a tryptophan alkyl ester of formula (IV)

- 31 -



(IV)

(where Alk is as previously defined) or a salt thereof (e.g., the hydrochloride salt) according to either of the following procedures (a) and (b). Procedure (b) is only suitable for preparing *cis* isomers of formula (III) and can be particularly suitable for preparing individual *cis* enantiomers of formula (III) from D- or L- tryptophan alkyl esters as appropriate.

Procedure (a)

This comprises a Pictet-Spengler cyclization between a compound of formula (IV) and an aldehyde R^2CHO . The reaction can be conveniently effected in a suitable solvent such as a halogenated hydrocarbon (e.g., dichloromethane) or an aromatic hydrocarbon (e.g., toluene) in the presence of an acid, such as trifluoroacetic acid. The reaction conveniently can be carried out at a temperature of from $-20^\circ C$ to reflux to provide a compound of formula (III) in one step. The reaction also can be carried out in a solvent such as an aromatic hydrocarbon (e.g., benzene or toluene) under reflux, optionally using a Dean-Stark apparatus to trap the water produced.

- 32 -


The reaction provides a mixture of cis and trans isomers which can be either individual enantiomers or racemates of pairs of cis or trans isomers, depending upon whether racemic or enantio-merically pure tryptophan alkyl ester was used as the starting material. Individual cis or trans enantiomers conveniently can be separated from mixtures thereof by fractional crystallization or by chromatography (e.g., flash column chromatography) using appropriate solvents and eluents. Similarly, pairs of cis and trans isomers can be separated by chromatography (e.g., flash column chromatography) using appropriate eluents. An optically pure trans isomer also can be converted to an optically pure cis isomer using suitable epimerization procedures. One such procedure comprises treating the trans isomer or a mixture (e.g., 1:1 mixture) of cis and trans isomers with methanolic or aqueous hydrogen chloride at a temperature of from 0°C to the refluxing temperature of the solution. The mixture then can be subjected to chromatography (e.g., flash column chromatography) to separate the resulting diastereoisomers, or in the procedure utilizing aqueous hydrogen chloride, the desired cis isomer precipitates out as the hydrochloride salt which then can be isolated by filtration.

Procedure (b)

This comprises a four-step procedure from a compound of formula (IV) or a salt thereof (e.g., the hydrochloride salt). The procedure is particularly suitable for preparing a 1R, 3R isomer of

- 33 -

formula (III) from a D-tryptophan alkyl ester of formula (IV) or a salt thereof (e.g., the hydrochloride salt). Thus, a first step (i) comprises treating a compound of formula (IV) with an acid halide R^2COHal (where Hal is as previously defined) in the presence of a base, e.g., an organic base such as a trialkylamine (for example, triethylamine), to provide a compound of formula (V).




(V)

The reaction can be conveniently carried out in a suitable solvent, such as a halogenated hydrocarbon (e.g., dichloromethane) or an ether (e.g., tetrahydrofuran), and at a temperature of from $-20^{\circ}C$ to $+40^{\circ}C$.


Step (ii) comprises treating a compound of formula (V) with an agent to convert the amide group to a thioamide group. Suitable sulfurating agents are well known in the art. Thus, for example, the reaction can be conveniently effected by treating (V) with Lawesson's reagent. This reaction can be conveniently carried out in a suitable solvent, such as ether (e.g., dimethoxyethane) or an aromatic hydrocarbon (e.g., toluene), at an elevated temperature, such as from $40^{\circ}C$ to $80^{\circ}C$ to provide a compound of formula (VI)

- 34 -



(VI)

Step (iii) comprises treating a compound of formula (VI) with a suitable agent to provide a compound of formula (VII)



(VII)


wherein Hal is a halogen atom, e.g., iodine. The reaction can be conveniently effected by treating (VI) with an alkylating agent, such as a methyl halide (e.g., methyl iodide), or an acylating agent, such as an acetyl halide (e.g., acetyl chloride), in a suitable solvent, such as a halogenated hydrocarbon (e.g., dichloromethane) at an elevated temperature (e.g., under reflux).

In step (iv), the resulting iminium halide of formula (VII) can be treated with a reducing agent, such as a boron hydride, e.g., sodium borohydride, to provide the desired compound of formula (III). The reduction can be conveniently effected

- 35 -

at a low temperature, e.g., within the range of -100°C to 0°C, in a suitable solvent, such as an alcohol (e.g., methanol).

There is further provided by the present invention a process (B) for preparing a compound of formula (I), wherein R¹ and R³ together represent a 3- or 4-membered alkyl or alkenyl chain, which process (B) comprises cyclization of a compound of formula (VIII)




(VIII)

wherein Alk represents C₁₋₆alkyl and R¹ and R³ together represent a 3- or 4-membered chain, both as hereinbefore described. The cyclization is suitably carried out in an organic solvent or solvents, such as an alcoholic solvent (e.g., methanol), and optionally an ether solvent such as tetrahydrofuran, and in the presence of a reducing agent, aptly a palladium catalyst, such as palladium on carbon.

Conveniently, a compound of formula (VIII) is prepared by reaction of a compound of formula (III) as hereinbefore described with a compound of formula (IX)


- 36 -



(IX)

wherein Hal represents a halogen atom as hereinbefore described, R¹ and R³ together represent a 3- or 4-membered chain as hereinbefore described, and R⁴ represents a protecting group, suitably a benzyloxycarbonyl group or the like. Typically, the reaction is carried out in a chlorinated organic solvent, such as dichloromethane, and a tertiary amine, such as triethylamine or the like.

According to a further aspect of the present invention, there is provided a process (C) for preparing a compound of formula (I) wherein R³ represents C₁₋₃alkyl, which process comprises cyclization of a compound of formula (X)



(X)

wherein Alk represents C₁₋₆alkyl as hereinbefore described and R⁵ represents C₂₋₅alkyl, substituted at C₁ by a halogen atom, the halogen atom being as

- 37 -

hereinbefore described. Suitably, the cyclization is achieved by reflux for many hours, such as 22 to 26 hours, in the presence of an ether solvent, such as tetrahydrofuran, and a suitable amine as hereinafter described in the accompanying examples.

Aptly, a compound of formula (X) can be prepared from a compound of formula (III) by suitable acylation techniques, such as reaction with a C₃₋₆-carboxylic acid, substituted at C-2 by a halogen atom in a halogenated organic solvent, such as dichloromethane.

Compounds of formula (I) can be converted to other compounds of formula (I). Thus, for example, when R² is a substituted benzene ring, it may be necessary or desirable to prepare the suitably substituted compound of formula (I) subsequent to process (A), (B), or (C), as above. Examples of appropriate interconversions include nitro to amino or aralkyloxy to hydroxy by suitable reducing means (e.g., using a reducing agent such as SnCl₂ or a palladium catalyst, such as palladium-on-carbon), or amino to substituted amino, such as acylamino or sulphonylamino using standard acylating or sulphonylating conditions. In the case where R² represents a substituted bicyclic system, suitable interconversion can involve removal of a substituent, such as by treatment with a palladium catalyst (e.g., palladium-on-carbon) whereby, for example, a benzyl substituent can be removed from a suitable bicyclic system.

The pharmaceutically acceptable acid addition salts of the compounds of formula (I), which contain a basic center, can be treated with a

- 38 -

suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt can be formed or interconverted using ion-exchange resin techniques.

Compounds of the invention can be isolated in association with solvent molecules by crystallization from or evaporation of an appropriate solvent.

Thus, according to a further aspect of the invention, we provide a process for preparing a compound of formula (I) or a salt or solvate (e.g., hydrate) thereof which comprises process (A), (B), or (C) as hereinbefore described followed by

- (i) an interconversion step, and/or
- either
- (ii) salt formation, or
- (iii) solvate (e.g., hydrate) formation.

There is further provided by the present invention compounds of formulae (II), (VIII), (X), and further compounds of formulae (III), (V), (VI), and (VII), with the exception for compounds (III), (V), (VI), and (VII), wherein R^0 is hydrogen, R^2 is phenyl, and Alk is methyl.

The pharmaceutically acceptable acid addition salts of the compounds of formula (I) which contain a basic center can be prepared in a conventional manner. For example, a solution of the free base can be treated with a suitable acid, either

- 39 -

neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of
5 a compound of formula (I) with a suitable base. Both types of salt can be formed or interconverted using ion-exchange resin techniques.

Thus, according to a further aspect of the invention, a method for preparing a compound of
10 formula (I) or a salt or solvate (e.g., hydrate) is provided, wherein the method comprises process (A), (B), or (C) as hereinbefore described, followed by (i) salt formation, or (ii) solvate (e.g., hydrate)
15 formation. The method of preparing the following Intermediates 1 through 92 and Examples 1 through 125, and characterization of the compounds, can be found in published PCT applications WO 95/19978, WO 97/03985, and WO 97/03675, incorporated herein by
20 reference.

Intermediates 1 and 2

Methyl 1,2,3,4-tetrahydro-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis
25 and trans isomers

Intermediates 3 and 4

Methyl 1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans
30 isomers

- 40 -

Intermediate 5

Methyl 1,2,3,4-tetrahydro-1-(3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer

5 Intermediates 6 and 7

Methyl 1,2,3,4-tetrahydro-1-(4-ethoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

10 Intermediates 8 and 9

Methyl 1,2,3,4-tetrahydro-1-(2,3-dihydrobenzo[b]-furan-5-yl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

15 Intermediates 10 and 11

Methyl 1,2,3,4-tetrahydro-1-(3,4-ethylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

20 Intermediate 12

Methyl 1,2,3,4-tetrahydro-1-(2-chlorophenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, mixture of cis and trans isomers

25 Intermediates 13 and 14

Methyl 1,2,3,4-tetrahydro-1-(4-chlorophenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

30 Intermediates 15 and 16

Methyl 1,2,3,4-tetrahydro-1-(3,4-dichlorophenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

- 41 -

Intermediate 17

Methyl 1,2,3,4-tetrahydro-1-(1,2,3,4-tetrahydro-6-naphthyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer

5

Intermediates 18 and 19

Methyl 1,2,3,4-tetrahydro-1-(2-naphthyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

10

Intermediates 20 and 21

Methyl 1,2,3,4-tetrahydro-1-(2-thienyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

Intermediates 22 and 23

15

Ethyl 1,2,3,4-tetrahydro-1-(3-thienyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

Intermediates 24 and 25

20

Methyl 1,2,3,4-tetrahydro-1-(5-bromo-2-thienyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

Intermediates 26 and 27

25

Methyl 1,2,3,4-tetrahydro-1-(4-bromo-2-thienyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

Intermediate 28

30

Methyl 1,2,3,4-tetrahydro-1-(3-furyl)-9H-pyrido[3,4-b]indole-3-carboxylate, mixture of cis and trans isomers

- 42 -

Intermediates 29 and 30

Ethyl 1,2,3,4-tetrahydro-1-(5-methyl-2-furyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

5

Intermediates 31 and 32

Ethyl 1,2,3,4-tetrahydro-1-(4-methylphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

10

Intermediates 33 and 34

Methyl 1,2,3,4-tetrahydro-1-(3-methylphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

15

Intermediates 35 and 36

Methyl 1,2,3,4-tetrahydro-1-(4-trifluoromethylphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

20

Intermediates 37 and 38

Ethyl 1,2,3,4-tetrahydro-1-(4-cyanophenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

25

Intermediate 39

Methyl 1,2,3,4-tetrahydro-1-(4-hydroxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer

30

Intermediate 40

Methyl 1,2,3,4-tetrahydro-1-(3-hydroxy-4-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer

- 43 -

Intermediate 41

Methyl 1,2,3,4-tetrahydro-1-(4-hydroxy-3-methoxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer

5

Intermediate 42

Methyl 1,2,3,4-tetrahydro-1-(4-ethylphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

10

Intermediates 43 and 44

Methyl 1,2,3,4-tetrahydro-1-(4-isopropylphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

15

Intermediates 45 and 46

Ethyl 1,2,3,4-tetrahydro-1-(4-nitrophenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

20

Intermediate 47

Ethyl 1,2,3,4-tetrahydro-1-(4-dimethylaminophenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, mixture of cis and trans isomers

25

Intermediates 48 and 49

Ethyl 1,2,3,4-tetrahydro-1-(3-pyridyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

30

Intermediates 50 and 51

Methyl 1,2,3,4 tetrahydro-6-fluoro-1-(3,4-methylene-dioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

- 44 -

Intermediates 52 and 53

Methyl 1,2,3,4-tetrahydro-6-fluoro-1-(4-methoxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

5

Intermediates 54 and 55

(1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(3,4-methylene-dioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and

10

(1S,3R)-methyl 1,2,3,4-tetrahydro-1-(3,4-methylene-dioxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate trans isomer

Intermediate 56

15

(1S, 3S) Methyl-1,2,3,4-tetrahydro-1-(3,4-methylene-dioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and

(1R, 3S) methyl-1,2,3,4-tetrahydro-1-(3,4-methylene-dioxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate,

20

trans isomer

Intermediates 57 and 58

(1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(4-methoxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and

25

(1S,3R)-methyl 1,2,3,4-tetrahydro-1-(4-methoxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, trans isomer

- 45 -

Intermediates 59 and 60

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-1-(3-chloro-4-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and

- 5 (1S, 3R)-methyl 1,2,3,4-tetrahydro-1-(3-chloro-4-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, trans isomer

Intermediates 61 and 62

- 10 (1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(2,3-dihydro-benzo[b]furan-5-yl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and
(1S,3R)-methyl 1,2,3,4-tetrahydro-1-(5-(2,3-dihydro-benzo[b]furan))-9H-pyrido[3,4-b]indole-3-carboxylate, trans isomer
- 15

Intermediates 63 and 64

- (1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(5-indanyl)-9H-pyrido[3,4-b]indole-3-carboxylate cis isomer and
20 (1S,3R)-methyl 1,2,3,4-tetrahydro-1-(5-indanyl)-9H-pyrido[3,4-b]indole-3-carboxylate trans isomer

Intermediate 65

- 25 Ethyl 1,2,3,4-tetrahydro-1-(4-trifluoromethoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis and trans isomers

Intermediate 66

- 30 Methyl 1,2,3,4-tetrahydro-1-(5-methyl-2-thienyl)-9H-pyrido [3,4-b]indole-3-carboxylate, cis and trans isomers

- 46 -

Intermediates 67 and 68

(1S,3R)-Methyl 1,2,3,4-tetrahydro-1-(3,4-methylene-
dioxyphe nyl)-9H-pyrido[3,4-b]indole-3-carboxylate
and

5 (1R,3R)-methyl 1,2,3,4-tetrahydro-1-(3,4-methylene-
dioxyphe nyl)-9H-pyrido[3,4-b]indole-3-carboxylate

Intermediate 69

10 (1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(3,4-methylene-
dioxyphe nyl)-9H-pyrido[3,4-b]indole-3-carboxylate

Intermediate 70

(R)-N⁹-(3,4-Methylenedioxyphe nylcarbonyl)-tryptophan
methyl ester

15

Intermediate 71

(R)-N⁹-(3,4-Methylenedioxyphe nylthiocarbonyl)-trypto-
phan methyl ester

20

Intermediate 72

(1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(3,4-methylene-
dioxyphe nyl)-9H-pyrido[3,4-b]indole-3-carboxylate

Intermediate 73

25 (1R,3R)-Methyl 1,2,3,4-tetrahydro-2-chloroacetyl-
(3,4-methylenedioxyphe nyl)-9H-pyrido[3,4-b]indole-3-
carboxylate

Intermediate 74

30 Methyl 1,2,3,4-tetrahydro-6-methyl-1-(3,4-methylene-
dioxyphe nyl)-9H-pyrido[3,4-b]indole-3-carboxylate,
cis and trans isomers

- 47 -

Intermediates 75 and 76

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-1-(7-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazinyl))-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and (1S, 3R)-
5 Methyl 1,2,3,4-tetrahydro-1-(7-(4-methyl-3,4-dihydro-2H-benzo[1,4]-oxazinyl))-9H-pyrido[3,4-b]indole-3-carboxylate, trans isomer

Intermediate 77

10 Methyl 1,2,3,4-tetrahydro-1-(5-(N-benzylindolinyl))-9H-pyrido[3,4-b]indole-3-carboxylate, mixture of (1R, 3R) and (1S, 3R) isomers

Intermediates 78 and 79

15 (1R, 3R)-Methyl 1,2,3,4-tetrahydro-1-(4-carbomethoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis isomer and (1S, 3R)-methyl 1,2,3,4-tetrahydro-1-(4-carbomethoxy-phenyl)-9H-pyrido[3,4-b]indole-3-carboxylate, trans isomer

20

Intermediate 80

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-2-[2-(benzyloxy-carbonyl)-R-prolyl]-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate

25

Intermediate 81

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-2-[2-(benzyloxy-carbonyl)-S-prolyl]-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate

30

- 48 -

Intermediate 82

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-2-(2-chloro-propionyl)-1-(3,4-methylenedioxyphenyl)-9H-pyrido-[3,4-b]indole-3-carboxylate

5

Intermediate 83

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-2-(2-chloro-propionyl)-1-(3,4-methylenedioxyphenyl)-9H-pyrido-[3,4-b]indole-3-carboxylate

10

Intermediates 84 and 85

(1R, 3R)-Methyl 1,2,3,4-tetrahydro-1-(3,4-dibenzyl-oxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate cis isomer and (1S, 3R)-methyl 1,2,3,4-tetrahydro-1-(3,4-dibenzyl-oxyphenyl)-9H-pyrido [3,4-b]indole-3-carboxylate trans isomer

15

Intermediate 86

(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-dibenzyl-oxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione

20

Intermediate 87

Methyl 1,2,3,4-tetrahydro-1-(5-(2-methylisoindol-1-yl))-9H-pyrido[3,4-b]indole-3-carboxylate, mixture of (1R,3R) and (1S,3R) isomers

25

- 49 -

Intermediates 88 and 89

(1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(5-benzo-
furanyl)-9H-pyrido[3,4-b]indole-3-carboxylate, cis
isomer and

5 (1S,3R)-methyl 1,2,3,4-tetrahydro-1-(5-benzo-
furanyl)-9H-pyrido[3,4-b]indole-3-carboxylate trans
isomer

Intermediate 90

10 (1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(5-benzo-
furanyl)-2-chloroacetyl-9H-pyrido[3,4-b]indole-3-
carboxylate

Intermediate 91

15 (1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(5-benzo-
furanyl)-2-(2-(S)-benzyloxycarbonylamino)propionyl)-
9H-pyrido[3,4-b]indole-3-carboxylate

Intermediate 92

20 (1R,3R)-Methyl 1,2,3,4-tetrahydro-1-(5-benzo-
furanyl)-2-[2-(S)-
benzyloxycarbonylmethylamino)propionyl]-9H-pyrido-
[3,4-b]indole-3-carboxylate

25 Example 1

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-
methylene-dioxypheyl)-pyrazino[2',1':6,1]pyrido-
[3,4-b]indole-1,4-dione--from Intermediate 1 and
methylamine.

30

The following compounds were obtained in a
similar manner:

- 50 -

Example 2

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-10-fluoro-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione--from butylamine and Intermediate 52.

Example 3

Trans-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphe-nyl)-pyrazino[2',1':6,1]pyrido-
[3,4-b]indole-1,4-dione--from methylamine and Intermediate 2.

Example 4

Cis-2,3,6,7,12,12a-hexahydro-6-(3,4-methylenedioxyphe-nyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from ammonia and Intermediate 1.

Example 5

Cis-2,3,6,7,12,12a-hexahydro-10-fluoro-6-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)-pyrazino-
[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from 2,2,2-trifluoroethylamine and Intermediate 52.

Example 6

Cis-2,3,6,7,12,12a-hexahydro-10-fluoro-2-methyl-6-(3,4-methylenedioxyphe-nyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 50.

- 51 -

Example 7

(6R, 12aS)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6.1]pyrido[3,4-b]indole-1,4-dione--from methylamine and the trans isomer of Intermediate 56.

Example 8

(6S, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino [2',1':6.1]pyrido-[3,4-b]indole-1,4-dione--from methylamine and Intermediate 55.

Example 9

Cis-2, 3, 6, 7, 12, 12a-hexahydro-2-[2-(2-pyridyl)-ethyl]-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1'-6,1]pyrido[3,4-b]indole-1,4-dione--from 2-(2-pyridyl)ethylamine and Intermediate 1.

Example 10

Cis-2,3,6,7,12,12a-hexahydro-2-(2-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from 2-pyridylmethylamine and Intermediate 1.

Example 11

Cis-2,3,6,7,12,12a-hexahydro-2-(3-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from 3-pyridylmethylamine and Intermediate 1.

- 52 -

Example 12

Cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from 4-pyridylmethyl-amine and Intermediate 1.

Example 13

Cis-2,3,6,7,12,12a-hexahydro-2-ethyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione--from ethylamine and Intermediate 1.

Example 14

Cis-2,3,6,7,12,12a-hexahydro-2-(2,2,2-trifluoroethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from 2,2,2-trifluoroethylamine and Intermediate 1.

Example 15

Cis-2,3,6,7,12,12a-hexahydro-6-(3,4-methylenedioxyphenyl)-2-propyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from propylamine and Intermediate 1.

Example 16

Cis-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from isopropylamine and Intermediate 1.

- 53 -

Example 17

Cis-2,3,6,7,12,12a-hexahydro-2-cyclopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylamine and Intermediate 1.

Example 18

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 1.

Example 19

Trans-2,3,6,7,12,12a-hexahydro-2-butyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 2.

Example 20

Cis-2,3,6,7,12,12a-hexahydro-2-cyclopropylmethyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 1.

Example 21

Cis-2,3,6,7,12,12a-hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopentylamine and Intermediate 1.

- 54 -

Example 22

Cis-2,3,6,7,12,12a-hexahydro-2-cyclohexyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclohexylamine and
5 Intermediate 1.

Example 23

Cis-2,3,6,7,12,12a-hexahydro-2-benzyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from benzylamine and Interme-
10 diate 1.

Example 24

Cis-2,3,6,7,12,12a-hexahydro-2-(4-fluorobenzyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-
15 pyrido[3,4-b]indole-1,4-dione--from 4-fluorobenzylamine and Intermediate 1.

Example 25

Cis-2,3,6,7,12,12a-hexahydro-6-(4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 3.

Example 26

Trans-2,3,6,7,12,12a-hexahydro-6-(4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 4.

Example 27

Cis-2,3,6,7,12,12a-hexahydro-2-ethyl-6-(4-methoxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from ethylamine and Intermediate 3.

- 55 -

Example 28

Cis-2,3,6,7,12,12a-hexahydro-6-(4-methoxyphenyl)-2-(2,2,2-trifluoroethyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from 2,2,2-trifluoroethylamine and Intermediate 3.

Example 29

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 3.

Example 30

Trans-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 4.

Example 31

Cis-2,3,6,7,12,12a-hexahydro-6-(4-methoxyphenyl)-2-cyclopropylmethylpyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 3.

Example 32

Cis-2,3,6,7,12,12a-hexahydro-2-benzyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from benzylamine and Intermediate 3.

Example 33

Cis-2,3,6,7,12,12a-hexahydro-6-(3-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 5.

- 56 -

Example 34

Cis-2,3,6,7,12,12a-hexahydro-6-(4-ethoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 6.

5

Example 35

Cis-2,3,6,7,12,12a-hexahydro-6-(4-ethoxyphenyl)-2-cyclopropylmethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 6.

10

Example 36

Cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]-furan-5-yl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 8.

15

Example 37

Cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]-furan-5-yl)-2-cyclopropylmethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 8.

20

Example 38

Cis-2,3,6,7,12,12a-hexahydro-6-(3,4-ethylenedioxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 10.

25

- 57 -

Example 39

Cis-2,3,6,7,12,12a-hexahydro-6-(3,4-ethylenedioxyphenyl)-2-cyclopropylmethyl-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 10.

Example 40

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(2-chlorophenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 12.

Example 41

Cis-2,3,6,7,12,12a-hexahydro-6-(4-chlorophenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 13.

Example 42

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-chlorophenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 13.

Example 43

Cis-2,3,6,7,12,12a-hexahydro-6-(3,4-dichlorophenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 15.

Example 44

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-phenyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and cis-methyl 1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate.

- 58 -

Example 45

Cis-2,3,6,7,12,12a-hexahydro-2-benzyl-6-phenyl-
pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-
dione--from benzylamine and cis-methyl-1,2,3,4-
5 tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-
carboxylate.

Example 46

Trans-2,3,6,7,12,12a-hexahydro-2-benzyl-6-phenyl-
10 pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-
dione--from benzylamine and cis-methyl-1,2,3,4-
tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-
carboxylate.

15 Example 47

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(1,2,3,4-
tetrahydro-6-naphthyl)-pyrazino[2',1':6,1]pyrido-
[3,4-b]indole-1,4-dione--from methylamine and
Intermediate 17.

20

Example 48

Cis-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(1,2,3,4-
tetrahydro-6-naphthyl)-pyrazino[2',1':6,1]pyrido-
[3,4-b]indole-1,4-dione--from isopropylamine and
25 Intermediate 17.

Example 49

Cis-2,3,6,7,12,12a-hexahydro-2-cyclopropylmethyl-6-
(1,2,3,4-tetrahydro-6-naphthyl)-pyrazino[2',1':-
30 6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropyl-
methylamine and Intermediate 17.

- 59 -

Example 50

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(2-naphthyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 18.

5

Example 51

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(2-thienyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 20.

10

Example 52

Cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 24.

15

Example 53

Cis-2,3,6,7,12,12a-hexahydro-6-(4-bromo-2-thienyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 26.

20

Example 54

Cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-cyclopropylmethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 24.

25

Example 55

Cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-cyclopentyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopentylamine and Intermediate 24.

30

- 60 -

Example 56

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(5-methyl-2-thienyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and the cis isomer of
5 Intermediate 66. —

Example 57

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3-thienyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 22.
10

Example 58

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(3-thienyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 22.
15

Example 59

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3-furyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and the cis isomer of
20 Intermediate 28.

Example 60

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(5-methyl-2-furyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 29.
25

Example 61

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(4-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 31.
30

- 61 -

Example 62

Cis-2,3,6,7,12,12a-hexahydro-2-isopropyl-6-(4-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione--from isopropylamine and

5 Intermediate 31.

Example 63

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 31.

10

Example 64

Cis-2,3,6,7,12,12a-hexahydro-2-cyclopropylmethyl-6-(4-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione--from cyclopropylmethylamine and Intermediate 31.

15

Example 65

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3-methylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 33.

20

Example 66

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-trifluoromethylphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione--from butylamine and Intermediate 35.

25

Example 67

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(4-trifluoromethoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and the cis isomer of Intermediate 65.

30

- 62 -

Example 68

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(4-hydroxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 39.

5

Example 69

Cis-2,3,6,7,12,12a-hexahydro-6-(3-hydroxy-4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 40.

10

Example 70

Cis-2,3,6,7,12,12a-hexahydro-6-(4-hydroxy-3-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 41.

15

Example 71

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-cyanophenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 37.

20

Example 72

Cis-2,3,6,7,12,12a-hexahydro-6-(4-ethylphenyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from isopropylamine and the cis isomer of Intermediate 42.

25

Example 73

Cis-2,3,6,7,12,12a-hexahydro-6-(4-ethylphenyl)-2-cyclopropylmethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and the cis isomer of Intermediate 42.

30

- 63 -

Example 74

Cis-2,3,6,7,12,12a-hexahydro-6-(4-isopropylphenyl)-
2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-
dione--from methylamine and Intermediate 43.

5

Example 75

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-nitro-
phenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-
dione--from butylamine and Intermediate 45.

10

Example 76

Cis-2,3,6,7,12,12a-hexahydro-6-(4-dimethylamino-
phenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-
b]indole-1,4-dione--from methylamine and the cis
isomer of Intermediate 47.

15

Example 77

Cis-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3-pyridyl)-
pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-
dione--from methylamine and Intermediate 48.

20

Example 78

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-
methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-
b]indole-1,4-dione--Intermediate 54 and methylamine.

25

The following compounds were obtained in a
similar manner:

- 64 -

Example 79

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-isopropyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from isopropylamine and Intermediate 54.

Example 80

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-butyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from butylamine and Intermediate 54.

Example 81

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-isobutyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from isobutylamine and Intermediate 54.

Example 82

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from cyclopentylamine and Intermediate 54.

Example 83

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)-2-cyclohexylmethyl-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from cyclohexylmethylamine and the cis isomer of Intermediate 56.

- 65 -

Example 84

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopropyl-methyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from cyclopropyl-methylamine and Intermediate 57.

Example 85

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-butyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-indole-1,4-dione--from butylamine and Intermediate 57.

Example 86

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--rom cyclopentylamine and Intermediate 57.

Example 87

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3-chloro-4-methoxyphenyl)-2-cyclopropylmethyl-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 59.

Example 88

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3-chloro-4-methoxyphenyl)-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from cyclopentylamine and Intermediate 59.

- 66 -

Example 89

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido-[3,4-b]indole-1,4-dione--from methylamine and
5 Intermediate 59.

Example 90

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-isopropyl-6-(3-chloro-4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido-[3,4-b]indole-1,4-dione--from isopropylamine and
10 Intermediate 59.

Example 91

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(2,3-dihydro-benzo[b]furan-5-yl)-2-methyl-pyrazino[2',1':6,1]-pyrido[3,4-b]indole-1,4-dione--from methylamine and
15 Intermediate 61.

Example 92

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(2,3-dihydro-benzo[b]furan-5-yl)-2-methylcyclopropyl-pyrazino-[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from
20 methylcyclopropylamine and Intermediate 61.

25 Example 93

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-indanyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from methylamine and Intermediate 63.

- 67 -

Example 94

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-indanyl)-2-cyclopropylmethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from cyclopropylmethylamine and Intermediate 63.

Example 95

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from Intermediate 73 and methylamine.

Example 96

Cis-2,3,6,7,12,12a-hexahydro-2,10-dimethyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure used to prepare Example 1, but starting from methylamine and the cis isomer of Intermediate 74.

Example 97

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-(3,4-dimethoxybenzyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as used to prepare Example 78, but starting from veratrylamine and Intermediate 54.

Example 98

Cis-2,3,6,7,12,12a-hexahydro-6-(4-aminophenyl)-2-butyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from Example 75.

- 68 -

Example 99

Cis-2,3,6,7,12,12a-hexahydro-6-(4-acetamidophenyl)-
2-butyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-
dione--from Example 98.

5

Example 100

Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methyl-
sulfonamidophenyl)-pyrazino[2',1':6,1]pyrido[3,4-
b]indole-1,4-dione--from Example 98.

10

Example 101

(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methyl-
enedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]-
indole-1,4-dione--from the same procedure as Example
100 starting from ammonia and Intermediate 54.

15

Example 102

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylene-
dioxyphenyl)-2-(2-propynyl)-pyrazino[2',1':6,1]-
pyrido[3,4-b]indole-1,4-dione--from the same pro-
cedure as Example 100 starting from propargylamine
and Intermediate 54.

20

Example 103

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-(3,4-methylene-
dioxybenzyl)-6-(3,4-methylenedioxyphenyl)-pyrazino-
[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the
same procedure as Example 100 starting from piper-
onylamine and Intermediate 54.

30

- 69 -

Example 104

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-(3,4-dimethoxyphenethyl)-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as Example 100 3,4-dimethoxyphenethylamine and Intermediate 54.

Example 105

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-furfuryl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as Example 100 starting from furfurylamine and Intermediate 54.

Example 106

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)-2-(2-thienylmethyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as Example 100 starting from 2-thiophenemethylamine and Intermediate 54.

Example 107

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(4-methoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as Example 100 starting from methylamine and Intermediate 57.

Example 108

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-ethyl-6-(4-methoxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as Example 100 starting from ethylamine and Intermediate 57.

- 70 -

Example 109

(6R,12aR)-2,3,6,7,12,12a-hexahydro-6-(7-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazinyl))-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--
5 from the same procedure as Example 100 starting from Intermediate 75.

Example 110

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-(N-benzyl-indolinyl))-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as
10 Example 100 starting from Intermediate 77.

Example 111

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-indolinyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from Example 110.
15

Example 112

Cis-2,3,6,7,12,12a-hexahydro-6-(4-ethylphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as Example 100 starting from methylamine and the cis isomer of Intermediate 42.
20

Example 113

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(4-carbomethoxyphenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from the same procedure as
30 Example 100 starting from Intermediate 78 (cis isomer) and methylamine.

- 71 -

Example 114

(5aR,12R,14aR)-1,2,3,5a,6,11,12,14a-Octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo[1'',2'':4',5']-pyrazino[2',1':6,1]pyrido[3,4-b]indole-5-1,4-dione--
5 from Intermediate 80. --

Example 115

(5aR,12R,14aS)-1,2,3,5,6,11,12,14a-Octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo[1'',2'':4',5']-
10 pyrazino[2',1':6,1]pyrido[3,4-b]indole-5-1,4-dione--
from Intermediate 81.

Example 116

(3R,6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-
15 6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-
pyrido[3,4-b]indole-1,4-dione--from Intermediate 82
and methylamine.

Example 117

(3S,6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-
20 6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]-
pyrido[3,4-b]indole-1,4-dione--from Intermediate 83
and methylamine.

25 Example 118

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-dihydroxy-
phenyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]-
indole-1,4-dione--from Intermediate 86.

- 72 -

Example 119

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(5-(2-methylisoindoliny))pyrazino[2',1':6,1]pyrido[3,4b]indole-1,4-dione--from Intermediate 87 and methyl-
5 amine.

Example 120

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2'1':6,1]pyrido[3,4-b]-
10 indole-1,4-dione--and Intermediate 91 and methyl-amine.

Example 121

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from ammonia and Intermediate 91.

Example 122

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from Intermediate 91.

Example 123

(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from Intermediate 92.

Example 124

(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(t-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione--from Intermediate 93.

- 73 -

Example 125

(3S, 6R, 12aR)-2, 3, 6, 7, 12, 12a-Hexahydro-3-methyl-6-(3, 4-methylenedioxyphenyl)-pyrazino[2', 1':6, 1]-pyrido[3, 4-b]indole-1, 4-dione--from Intermediate 43 and ammonia.

TABLETS FOR ORAL ADMINISTRATIONA. Direct Compression

1.	mg/tablet
Active Ingredient	50.0
Crospovidone USNF	8.0
Magnesium Stearate Ph Eur	1.0
Anhydrous Lactose	141.0

The active ingredient was sieved and blended with the excipients. The resultant mix was compressed into tablets.

2.	mg/tablet
Active Ingredient	50.0
Colloidal Silicon Dioxide	0.5
Crospovidone	8.0
Sodium Lauryl Sulfate	1.0
Magnesium Stearate Ph Eur	1.0
Microcrystalline Cellulose USNF	139.5

- 74 -

The active ingredient was sieved and blended with the excipients. The resultant mix was compressed into tablets.

5 B. Wet Granulation

	1.	mg/tablet
	Active ingredient	50.0
	Polyvinylpyrrolidone	150.0
10	Polyethylene glycol	50.0
	Polysorbate 80	10.0
	Magnesium Stearate Ph Eur	2.5
	Croscarmellose Sodium	25.0
	Colloidal Silicon Dioxide	2.5
15	Microcrystalline Cellulose USNF	210.0

The polyvinylpyrrolidone, polyethylene glycol, and polysorbate 80 were dissolved in water. The resultant solution was used to granulate the active ingredient. After drying, the granules were screened then extruded at elevated temperatures and pressures. The extrudate was milled and/or screened, then was blended with the microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The resultant mix was compressed into tablets.

- 75 -

2.	mg/tablet
Active Ingredient	50.0
Polysorbate 80	3.0
Lactose Ph Eur	178.0
Starch BP	45.0
Pregelatinized Maize Starch BP	22.5
Magnesium Stearate BP	1.5

The active ingredient was sieved and blended with the lactose, starch, and pregelatinized maize starch. The polysorbate 80 was dissolved in purified water. Suitable volumes of the polysorbate 80 solution were added and the powders were granulated. After drying, the granules were screened and blended with the magnesium stearate. The granules were then compressed into tablets.

Tablets of other strengths may be prepared by altering the ratio of active ingredient to the other excipients.

FILM COATED TABLETS

The aforementioned tablet formulations were film coated.

- 76 -

Coating Suspension	% w/w
Opadry white †	13.2
Purified water Ph Eur	to 100.0*

* The water did not appear in the final product. The maximum theoretical weight of solids applied during coating was 20 mg/tablet.

† Opadry white is a proprietary material obtainable from Colorcon Limited, UK, which contains hydroxypropyl methylcellulose, titanium dioxide, and triacetin.

The tablets were film coated using the coating suspension in conventional film coating equipment.

CAPSULES

1.	mg/capsule
Active Ingredient	50.0
Lactose	148.5
Polyvinylpyrrolidone	100.0
Magnesium Stearate	1.5

The active ingredient was sieved and blended with the excipients. The mix was filled into size No. 1 hard gelatin capsules using suitable equipment.

- 77 -

2.	mg/capsule
Active Ingredient	50.0
Microcrystalline Cellulose	233.5
Sodium Lauryl Sulfate	3.0
Crospovidone	12.0
Magnesium Stearate	1.5

10 The active ingredient was sieved and blended with the excipients. The mix was filled into size No. 1 hard gelatin capsules using suitable equipment.

15 Other doses can be prepared by altering the ratio of active ingredient to excipient, the fill weight, and, if necessary, changing the capsule size.

3.	mg/capsule
Active Ingredient	50.0
Labrafil M1944CS	to 1.0 ml

20 The active ingredient was sieved and blended with the Labrafil. The suspension was filled into soft gelatin capsules using appropriate equipment.

Inhibitory Effect on cGMP-PDE

30 cGMP-PDE activity of compounds of the present invention was measured using a one-step assay adapted from Wells et al., *Biochim. Biophys.*

- 78 -

Acta, 384, 430 (1975). The reaction medium contained 50 mM Tris-HCl, pH 7.5, 5 mM magnesium acetate, 250 μ g/ml 5'-Nucleotidase, 1 mM EGTA, and 0.15 μ M 8-[H³]-cGMP. The enzyme used was a human recombinant PDE5 (ICOS Corp., Bothell, Washington).

Compounds of the invention were dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

The IC₅₀ values for the compounds examined were determined from concentration-response curves typically using concentrations ranging from 10 nM to 10 μ M. Tests against other PDE enzymes using standard methodology also showed that compounds of the invention are highly selective for the cGMP-specific PDE enzyme.

cGMP Level Measurements

Rat aortic smooth muscle cells (RSMC), prepared according to Chamley et al., *Cell Tissue Res.*, 177, 503-522 (1977), were used between the 10th and 25th passage at confluence in 24-well culture dishes. Culture media was aspirated and replaced with PBS (0.5 ml) containing the compound tested at the appropriate concentration. After 30 minutes at 37°C, particulates guanylate cyclase was stimulated by addition of ANF (100 nM) for 10 minutes. At the end of incubation, the medium was withdrawn, and two extractions were performed by addition of 65% ethanol (0.25 ml). The two ethanol-ic extracts were pooled and evaporated until dryness, using a Speed-vac system. cGMP was measured

- 79 -

after acetylation by scintillation proximity immuno-
assay (AMERSHAM). The EC_{50} values are expressed as
the dose-giving half of the stimulation at saturat-
ing concentrations.

5

Biological Data

The compounds according to the present
invention were typically found to exhibit an IC_{50}
10 value of less than 500 nM and an EC_{50} value of less
than 5 μM . *In vitro* test data for representative
compounds of the invention is given in the following
table:

- 80 -

Table 1: *In vitro* Results

Example No.	IC ₅₀ (nM)	EC ₅₀ (μM)
12	10	0.15
36	<10	0.5
52	20	0.8
63	30	0.35
78	2	0.2
79	<10	0.15
82	20	0.5
84	10	0.4
89	10	<0.1
95	2	0.2
101	10	0.3
115	<10	0.4
117	2	0.2
120	15	0.6
121	20	<1
122	30	<1
123	8	<1
124	8	<1

The hypotensive effects of compounds according to the invention as identified in Table 2 were studied in conscious spontaneously hypertensive rats (SHRs). The compounds were administered orally at a dose of 5 mg/kg in a mixture of 5% DMF and 95% olive oil. Blood pressure was measured from a catheter inserted in the carotid artery and recorded for five hours after administration. The results

- 81 -

are expressed as Area Under the Curve (AUC) from 0 to 5 hours, mm Hg·hours of the fall in blood pressure over time.

5

10

15

20

Table 2. <i>In vivo</i> results	
Example No.	SHR AUC PO (mm Hg.h)
36	99
63	95
79	171
82	111
84	77
89	117
95	135
101	136
120	137
121	93
122	108
123	101
124	89

25

Obviously, many modifications and variations of the invention as hereinbefore set forth can be made without departing from the spirit and scope thereof, and, therefore, only such limitations should be imposed as are indicated by the appended claims.


- 82 -

WHAT IS CLAIMED IS:

1. A combination comprising:

(a) a compound represented by a formula

(I)



(I)

and salts and solvates thereof, in which:

R^0 represents hydrogen, halogen or C_{1-6} -alkyl;

R^1 represents hydrogen, C_{1-6} alkyl, C_{2-6} -alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, aryl C_{1-3} alkyl, or heteroaryl- C_{1-3} alkyl;

R^2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine or an optionally substituted bicyclic ring



attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring

- 83 -

A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and

R³ represents hydrogen or C₁₋₃alkyl, or R¹ and R³ together represent a 3- or 4- membered alkyl or alkenyl chain; and

(b) a second therapeutically active agent,

for simultaneous, separate, or sequential use in the treatment of condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit.

2. A pharmaceutical formulation comprising a combination according to claim 1, together with a pharmaceutically acceptable diluent or carrier.

- 84 -

3. The combination of claim 1 wherein the condition is stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, congestive heart failure, acute respiratory distress syndrome, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, myocardial infarction, post-bypass surgery graft stenosis, a peripheral vascular disease, a vascular disorder, Raynaud's disease, thrombocythemia, an inflammatory disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, osteoporosis, preterm labor, benign prostatic hypertrophy, a gut motility disorder, or irritable bowel syndrome.

4. The combination of claim 1 wherein the condition is erectile dysfunction in a male or female animal.

5. The combination of claim 1 wherein the second therapeutically active agent comprises a vasodilator, prostaglandin E₁, prostacyclin, an α -adrenergic blocker, a mixed α , β -blocker, an α_2 -adrenergic blocker, an ACE inhibitor, an NEP inhibitor, a centrally acting dopaminergic agent, a vasoactive intestinal peptide, a calcium channel blocker, a thiazide, or a mixture thereof.

- 85 -

6. The combination of claim 5 wherein the vasodilator is selected from the group consisting of an organic nitrate, an organic nitrite, a thio-nitrite, a thionitrate, an S-nitrosothiol, a nitro-soprotein, a substituted furoxane, a substituted sydnonimine, a nitrosyl complex compound, nitric oxide, or a mixture thereof.

7. The combination of claim 5 wherein the vasodilator is selected from the group consisting of nitroglycerin, isosorbide dinitrate, pentaerythrityl tetranitrate, isosorbide-5-mononitrate, propatyl nitrate, trolnitrate, nicroandil, mannitol hexa-nitrate, inositol hexanitrate, N-[3-nitratopival-oyl]-6-cysteine ethyl ester, isoamyl nitrite, S-nitroso-N-acetyl-D,L-penicillamine, 1,2,5-oxadiazole-2-oxide, furazan-N-oxide, molsidomine, meso-carb, an iron nitrosyl compound, sodium nitroprus-side, nitric oxide, and mixtures thereof.

8. The combination of claim 1 wherein the second therapeutically active compound is selected from the group consisting of prostaglandin E1, prostocyclin, apomorphine, yohimbine, phentolamine, prazosin, carvedilol, and mixtures thereof.

9. A method of treating a condition where inhibition of a cGMP-specific PDE is of therapeutic benefit, in a human or a nonhuman animal body, comprising administering to said body a therapeutically effective amount of a combination of claim 1.

- 86 -

10. The method of claim 9 wherein the cGMP-specific PDE is PDE5.

11. The method of claim 9 comprising a prophylactic or curative treatment of erectile dysfunction in a male or female animal.

12. The method of claim 1 wherein the male or female animal is a human male or female animal.

13. The method of claim 9 wherein the treatment is an oral treatment.

- 87 -

14. A method of treating stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, acute respiratory distress syndrome, malignant hypertension, pheochromocytoma, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, a peripheral vascular disease, a vascular disorder, thrombocythemia, an inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, a gut motility disorder, postpercutaneous transluminal coronary or carotid angioplasty, post-bypass surgery graft stenosis, osteoporosis, preterm labor, benign prostatic hypertrophy, or irritable bowel syndrome, in a human or nonhuman animal body, said method comprising administering to said body a therapeutically effective amount of a combination of claim 1.

15. The method of claim 14 wherein the combination is administered orally.

INTERNATIONAL SEARCH REPORT

Int: nal Application No
PCT/US 99/19466

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4985 A61P9/08 A61P15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	WO 96 38131 A (GLAXO GROUP LTD.) 5 December 1996 (1996-12-05) page 1, line 3 - line 13 page 4, line 10 - line 35 page 7, line 23 -page 9, line 7 page 11, line 11 - line 28 claims 1,5,15,23-26,33,34 ---	1-13
X, Y	WO 97 03675 A (LABORATOIRE GLAXO WELLCOME S.A.) 6 February 1997 (1997-02-06) cited in the application page 1, line 3 -page 6, line 28 page 12, line 15 -page 17, line 27 claims 1-12 --- -/-	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

3 December 1999

Date of mailing of the international search report

10/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-3040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Economou, D

INTERNATIONAL SEARCH REPORT

Inter national Application No.

PCT/US 99/19466

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO 97 03985 A (LABORATOIRE GLAXO WELLCOME S.A.) 6 February 1997 (1997-02-06) cited in the application page 1, line 3 -page 5, line 33 claims 1-11 page 12, line 6 -page 17; table 2 ---	1-13
X,Y	WO 95 19978 A (LABORATOIRE GLAXO S.A.) 27 July 1995 (1995-07-27) cited in the application page 1, line 3 -page 9, line 19 page 71, line 21 -page 77 claims 1-15 ---	1-13
Y	WO 94 05661 A (PFIZER LTD.) 17 March 1994 (1994-03-17) page 1, paragraph 1 - paragraph 2 page 14 claims 1-9 ---	1-3,9, 10,12,13
Y	WO 96 27372 A (INTERNATIONAL MEDICAL INNOVATIONS, INC.) 12 September 1996 (1996-09-12) page 1, line 20 -page 8, line 13 claims 1-24 ---	1,2,4-13
Y	WO 96 34583 A (BAKER NORTON PHARMACEUTICALS, INC.) 7 November 1996 (1996-11-07) page 1, line 1 -page 13, paragraph 2 examples 4-7 claims 1-34 ---	1,2,4-13
Y	DE 42 20 264 A (CASSELLA AG.) 23 December 1993 (1993-12-23) page 5, line 60 -page 6, line 1 page 6, line 64 -page 7, line 20 claims 1-10 ---	1-13
Y	WO 95 29172 A (THERABEL RESEARCH S.A.) 2 November 1995 (1995-11-02) page 1, line 1 -page 2, paragraph 2 page 6, last paragraph -page 7, last paragraph ---	1-13
Y	WO 96 28142 A (VIVUS INCORPORATED) 19 November 1996 (1996-11-19) page 1, line 35 -page 2, line 2 page 6, line 19 -page 7, line 23 claims 1,12 ---	1,2,4-13
Y	WO 95 11683 A (THE UPJOHN COMPANY) 4 May 1995 (1995-05-04) page 2, line 11 - line 12 ---	1,2,4-13

-/-

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 99/19466

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 31368 A (R.P. SCHERER LTD.) 23 July 1998 (1998-07-23) claims 1,4 ---	1,2,4-13
Y	EP 0 611 248 A (B.M.R.A. CORPORATION B.V.) 17 August 1994 (1994-08-17) claims 1-11 ---	1,2,4-13
Y	WO 95 05172 A (ZONAGEN, INC.) 23 February 1995 (1995-02-23) claims 1-5 ---	1,2,4-13
Y	WO 92 11851 A (LARAGH J.H.) 23 July 1992 (1992-07-23) claims 1-13 -----	1,2,4-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/19466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9638131 A	05-12-1996	AU 6002696 A EP 0828479 A	18-12-1996 18-03-1998
WO 9703675 A	06-02-1997	AU 704955 B AU 6419196 A BR 9609758 A CA 2226784 A CN 1195290 A CZ 9800033 A EP 0839040 A HU 9900065 A JP 11509221 T NO 980153 A PL 324495 A SK 3998 A	13-05-1999 18-02-1997 26-01-1999 06-02-1997 07-10-1998 13-05-1998 06-05-1998 28-05-1999 17-08-1999 10-03-1998 25-05-1998 08-07-1998
WO 9703985 A	06-02-1997	AU 702324 B AU 6419296 A BR 9609780 A CA 2226761 A CN 1195349 A CZ 9800032 A EP 0846118 A HR 960321 A HU 9900006 A JP 11509535 T NO 980154 A PL 324527 A SK 3898 A US 5981527 A	18-02-1999 18-02-1997 09-03-1999 06-02-1997 07-10-1998 17-06-1998 10-06-1998 31-08-1998 28-04-1999 24-08-1999 10-03-1998 08-06-1998 04-11-1998 09-11-1999
WO 9519978 A	27-07-1995	AP 556 A AT 169018 T AU 689205 B AU 1574895 A AU 707055 B AU 7391298 A BG 100727 A BR 9506559 A CA 2181377 A CN 1143963 A CZ 9602116 A DE 69503753 D DE 69503753 T EP 0740668 A ES 2122543 T FI 962927 A HR 950023 A HU 74943 A IL 112384 A JP 9508113 T LV 11690 A LV 11690 B NO 963015 A NZ 279199 A PL 315559 A SG 49184 A SI 740668 T	07-11-1996 15-08-1998 26-03-1998 08-08-1995 01-07-1999 20-08-1998 28-02-1997 28-10-1997 27-07-1995 26-02-1997 11-06-1997 03-09-1998 21-01-1999 06-11-1996 16-12-1998 19-07-1996 30-04-1998 28-03-1997 16-08-1998 19-08-1997 20-02-1997 20-06-1997 09-09-1996 26-01-1998 12-11-1996 18-05-1998 28-02-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte nial Application No

PCT/US 99/19466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9519978 A		SK 94096 A US 5859006 A ZA 9500424 A	09-04-1997 12-01-1999 27-09-1995
WO 9405661 A	17-03-1994	AT 148118 T CA 2138298 A,C DE 69307712 D DE 69307712 T DK 656898 T EP 0656898 A ES 2096936 T FI 950889 A GR 3022852 T JP 2660103 B JP 7506838 T US 5591742 A	15-02-1997 17-03-1994 06-03-1997 15-05-1997 18-08-1997 14-06-1995 16-03-1997 27-02-1995 30-06-1997 08-10-1997 27-07-1995 07-01-1997
WO 9627372 A	12-09-1996	US 5698589 A AP 691 A AU 701328 B AU 5302596 A BR 9607974 A CA 2214418 A CN 1177294 A CZ 9702818 A EP 0814800 A HU 9801234 A JP 11501629 T NO 974075 A PL 322110 A SI 9620038 A SK 117597 A	16-12-1997 12-10-1998 28-01-1999 23-09-1996 13-01-1998 12-09-1996 25-03-1998 17-12-1997 07-01-1998 28-01-1999 09-02-1999 27-10-1997 05-01-1998 30-04-1998 14-01-1997
WO 9634583 A	07-11-1996	US 5646181 A AU 3395999 A AU 702338 B AU 5387796 A CA 2208666 A EP 0783283 A ZA 9603185 A	08-07-1997 05-08-1999 18-02-1999 21-11-1996 07-11-1996 16-07-1997 30-10-1996
DE 4220264 A	23-12-1993	CA 2098779 A EP 0575782 A HU 66288 A JP 7101947 A US 5424326 A ZA 9304381 A	21-12-1993 29-12-1993 28-11-1994 18-04-1995 13-06-1995 17-01-1994
WO 9529172 A	02-11-1995	HU 70750 A AU 694219 B AU 2415995 A BG 61974 B BG 100313 A BR 9506155 A CA 2163539 A CN 1128028 A CZ 9503163 A EP 0705255 A	30-10-1995 16-07-1998 16-11-1995 30-11-1998 31-07-1996 16-04-1996 02-11-1995 31-07-1996 15-05-1996 10-04-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No.

PCT/US 99/19466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9529172 A		FI 956156 A	20-12-1995
		HR 950249 A	31-10-1997
		JP 9503546 T	08-04-1997
		LT 95133 A, B	25-10-1996
		LV 11543 A	20-10-1996
		LV 11543 B	20-12-1996
		MD 950440 A	31-10-1997
		NO 955283 A	22-12-1995
		NZ 285149 A	26-06-1998
		PL 312183 A	01-04-1996
		SK 155195 A	07-05-1997
		US 5698535 A	16-12-1997
WO 9628142 A	19-09-1996	AU 5358896 A	02-10-1996
		BR 9607365 A	30-12-1997
		CA 2215307 A	19-09-1996
		CZ 9702784 A	15-04-1998
		DE 814775 T	25-06-1998
		EP 0814775 A	07-01-1998
		ES 2110380 T	16-02-1998
		HU 9801324 A	28-09-1998
		JP 10505611 T	02-06-1998
		NO 974062 A	15-09-1997
		NZ 305560 A	25-11-1998
		PL 322268 A	19-01-1998
		SK 124397 A	02-12-1998
		US 5820587 A	13-10-1998
WO 9511683 A	04-05-1995	AU 688792 B	19-03-1998
		AU 7716794 A	22-05-1995
		CN 1133561 A	16-10-1996
		EP 0725642 A	14-08-1996
		FI 961797 A	26-04-1996
		JP 9504529 T	06-05-1997
		NO 961718 A	29-04-1996
		NZ 273752 A	25-03-1998
		US 5741523 A	21-04-1998
		US 5770230 A	23-06-1998
WO 9831368 A	23-07-1998	AU 5671098 A	07-08-1998
		EP 0954314 A	10-11-1999
		NO 993520 A	16-09-1999
EP 0611248 A	17-08-1994	US 5567706 A	22-10-1996
WO 9505172 A	23-02-1995	AT 174795 T	15-01-1999
		AU 696815 B	17-09-1998
		AU 7523894 A	14-03-1995
		AU 9716898 A	04-03-1999
		BR 9407250 A	24-09-1996
		CA 2169071 A	23-02-1995
		CN 1128950 A	14-08-1996
		DE 69415535 D	04-02-1999
		DE 69415535 T	17-06-1999
		EP 0714300 A	05-06-1996
		ES 2127409 T	16-04-1999
		GR 3029500 T	28-05-1999
		JP 9501677 T	18-02-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/19466

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505172 A		NO 960549 A NZ 271567 A US 5565466 A ZA 9406123 A	12-04-1996 19-12-1997 15-10-1996 20-03-1995
WO 9211851 A	23-07-1992	US 5399581 A AU 9164791 A	21-03-1995 17-08-1992